1
Update on COPD & Asthma
Michael C. Peters, M.D. MASDivision of Pulmonary & Critical Care Medicine
Cardiovascular Research InstituteUniversity of California San Francisco
UCSF Primary Care MedicineSan Francisco, CAJune 24, 2016
Disclosures
• No Pharma Disclosures
• NHLBI - Asthma Clinical Research Network
• NHLBI – Severe Asthma Research Program
Update on the Management of COPD
2
To review COPD• COPD is a leading cause of death worldwide, and
mortality is increasing
• Exacerbations are the major complication of COPD•Associated with increased loss of lung function•And Mortality
• There are effective strategies for decreasing exacerbations
• COPD = Inflammatory Disease
• O2 therapy
• Pharmacologic Therapy: - More than symptoms -- Decreasing exacerbations- Change natural history?
•Pulmonary Rehab: reduces symptoms, depression, health care utilization; improves Q of L, exercise
COPD
• Smoking Cessation modifies natural history(lung function, mortality)
3
Question #1: Which of the following is NOT true?A. COPD mortality has plateauedB. Hospitalization for exacerbation
predicts mortalityC. Most exacerbations are caused by
infectionD. There are effective strategies for
decreasing exacerbations
C O PD m
o r ta l i t
y h as p l
a t . ..
H o sp i t a
l i z at i o n
f o r e x a
c e . ..
M os t e
x a ce r b
a t i on s a
r e .. .
T h er e a
r e ef f e c
t i v e s t r
a t e. . .
74%
4%17%
4%
Percent Change in Age-Adjusted Death Rates (US, 1965–1998)
Proportion of 1965 Rate
0.00.51.01.5
2.02.53.0
1965 – 1998 1965 – 1998 1965 – 1998 1965 – 1998 1965 – 1998–59% –64% –35% +163% –7%
CHD Stroke Other CVD COPD All othercauses
Hey Doc, Do I Have COPD????
Simel and RennieEvidence-based Clinical DiagnosisMcGraw Hill, 2008
•CHRONIC Obstructive Pulmonary Disease• NEED SPIROMETRY: FEV1/FVC < 0.70
Hey Doc, Do I Have COPD????
Simel and RennieEvidence-based Clinical DiagnosisMcGraw Hill, 2008
•CHRONIC Obstructive Pulmonary Disease• NEED SPIROMETRY: FEV1/FVC < 0.70
4
Respiratory Symptoms Smokers with Normal Pulmonary Function
Woodruff PG et al. N Engl J Med 2016;374:1811-1821
Symptom Scores
Prevalence of Symptoms and Risk of Respiratory Exacerbations
Woodruff PG et al. N Engl J Med 2016;374:1811-1821
Anthonisen et alJAMA 272:1497-505, 1994
• No benefit of screening adults with no symptoms
• No evidence that treating asymptomatic individuals prevents future symptoms, or reduces the subsequent decline in lung function.
Qaseen, Ann Int Med 155:179-91, 2011USPTF JAMA 2016
• Other: – Proteases/inflammation– Repetitive bacterial/viral infections – Genetics, especially α1-antitrypsin deficiency
NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease. April 2001; (Updated 2003).American Thoracic Society Statement Statement. Am J Respir Crit Care Med. 1995;152(suppl 5):S77-S120.
Risk Factors for COPD
5
Give it to me Straight. Is it BAD?
GOLD Guidelines 2007
GOLD 1: (Mild COPD) FEV1 > 80% predictedFEV1/FVC < 0.70
GOLD 2: (Moderate COPD) FEV1 50-80% predictedGOLD 3: (Severe COPD) FEV1 30-50% predictedGOLD 4: (Very Severe COPD) FEV1 <30% predicted
GOLD 2007N = 2164 stable COPDN = 337 “Healthy Smokers”N = 245 Never Smokers
Characterized Extensively at:Baseline3, 6, 12, 18, 24, 30, 36 months
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points
(ECLIPSE)Eur Respir J 2008; 31:869-73
2007 Gold Guidelines Not Good EnoughRespir Res 2010; 11:122
Agusti Respir Res 2010; 11:122Symptom Scores
Respir Res 2010; 11:122
Agusti Respir Res 2010; 11:122
2007 Gold Guidelines Not Good Enough
6
COPD Assessment: A New ModelRisk
GOLD
Clas
sifica
tion
of A
irflow
Lim
itatio
n
(C) (D)
(B)(A)
4
3
2
1
≥2 or
1
0
Risk
Exace
rbatio
n Hist
ory
mMRC 0-1CAT < 10 mMRC ≥ 2
CAT ≥10Symptoms(mMRC or CAT score)
When assessing risk, choose the highest risk according to GOLD grade or exacerbation history
Patient Category
Characteristics Spirometric Classification
Exacerbations per year
mMRC CAT
A Low Risk, Less Symptoms GOLD 1-2 ≤1 0-1 <10B Low Risk, More Symptoms GOLD 1-2 ≤1 ≥2 ≥10C High Risk, Less Symptoms GOLD 3-4 ≥2 0-1 <10D High Risk, More Symptoms GOLD 3-4 ≥2 ≥2 ≥10
GOLD Guidelines 2015
≥1 leading to hospital admission(no hospital admission)
Risk
GOLD
Clas
sifica
tion
of A
irflow
Lim
itatio
n
(C) (D)
(B)(A)
4
3
2
1
≥2 or
1
0
Risk
Exace
rbatio
n Hist
ory
mMRC 0-1CAT < 10 mMRC ≥ 2
CAT ≥10Symptoms(mMRC or CAT score)
When assessing risk, choose the highest risk according to GOLD grade or exacerbation history
GOLD Guidelines 2015
≥1 leading to hospital admission(no hospital admission)
Hospitalized Severe AECOPD and Mortality:Severity of AECOPD
1- no AECOPD 2- AECOPD ED
N = 305 men with COPDx 5 years
Soler-Cataluna Thorax 2005
3- AECOPD Hosp4- AECOPD Readmit
Question #2:Which of the Following Is the Best
Predictor of a Future Acute Exacerbations of COPD?
A. SpirometryB. SymptomsC. Smoking StatusD. Socio-Economic StatusE. Prior Exacerbation History
S p i ro m
e t ry
S y mp t o
m sS m
o k i ng S t
a t us
S o ci o - E
c o no m
i c St a t u
s
P r i or E x
a c er b a
t i o n H i s
t o ry
4% 8%
83%
0%4%
7
Predictors of Acute Exacerbations of COPD
Number of Exacerbations
≥2 vs. 0 1 vs. 0
Odds Ratio (95% CI) Odds Ratio (95% CI)
Exacerbation in Prior Year 5.7 (4.5-7.3) 2.2 (1.8-2.8)
FEV1 per 100ml decrease 1.1 (1.08-1.1) 1.1 (1.0-1.1)
SGRC (symptom score) per 4 points
1.1 (1.0-1.1) 1.1 (1.0 – 1.1)
GERD 2.1 (1.6-2.7) 1.6 (1.2-2.1)
WBC Count 1.1 (1-1.1) 1.1 (1.0-1.1)
Hurst NEJM 2010
Acute Exacerbations of COPD• Some patients seldom exacerbate• Some patients exacerbate frequently• Best predictor of ≥2 AECOPD/year
(“Frequent Exacerbator”) = previous frequent exacerbations
• Spirometry does not correlate well with clinical features of disease
• “Frequent Exacerbator” is a stable phenotype
COPD Exacerbations
• “Exacerbations are to COPD what myocardial infarctions are to coronary artery disease”
• “They are the acute, often trajectory-changing, and sometimes deadly manifestations of a chronic disease”
- Gerard J Criner, MDTemple University School of Medicine
Philadelphia, PA, USA
COPD Exacerbations (AECOPD): The Major Complication of COPD
• Characterized by episodic increases in dyspnea, sputum production and cough
• 16 million office visits/year• 500,000 hospitalizations/year• 110,000 deaths/year• $18 billion in direct health care costs
Mannino et al. MMWR Surveill Summ 2002; 51:1-16NHLBI: http://www.nhlbi.gov/resources/docs/02_chtbk.pdf
8
Question #3:Which of the Following DOES NOT
Reduce Acute Exacerbations of COPD?A. Inhaled CorticosteroidsB. Long Acting Beta AgonistC. Long Acting Muscarinic
AgonistsD. AzithromycinE. EMR training
I n ha l e d
C or t i c
o s te r o
i d s
L o ng A
c t i ng B e
t a Ag o n
i s t
L o ng A
c t i ng M
u s ca r i n
i c . ..
A z i th r o
m yc i n
E MR t r
a i n in g
0%7%
60%
33%
0%
Prevention of AECOPDAmerican College of Chest Physicians & Canadian
Thoracic Society Guideline• PICO (population, intervention, comparator,
outcome)• Literature Search
• Quality Assessment (AGREE II, DART)
• Grading Evidence (GRADEpro)• Recommendations (CHEST)
Criner et al. CHEST 147:894-942, 2015
Prevention of AECOPDRecommendations
• Influenza Vaccine (Grade 1B)• Pulmonary Rehab (Grade 1C)• Smoking Cessation (Grade 2C)• Pneumococcal Vaccine (Grade 2C)
Mod-severe-very severe; recent AECOPD<4 weeks
Criner et al. CHEST 147:894-942, 2015
Non-Pharmacologic Treatments/Vaccinations:• LAMA vs PBO (Grade 1A)• LABA vs PBO (Grade 1B)• LAMA vs LABA (Grade 1C)• COMBO Therapy vs MonoTherapy (Grade
1B,C)Criner et al. CHEST 147:894-942, 2015
Maintenance Inhaled Therapy:
Prevention of AECOPDRecommendations
9
• Macrolide (Grade 2A)(Frequent AECOPD despite Tx)
• Systemic Corticosteroids (Grade 2B)(For AECOPD – prevent next 30 days)
• Roflumilast (Grade 2A)(Chr Bronchitis, ≥1 AECOPD in year)
• Do not use statins for AECOPD (Grade 1B)Criner et al. CHEST 147:894-942, 2015
Oral Therapy:
Prevention of AECOPDRecommendations
NEJM 365:689-98, 2011
• NHLBI – COPD Clinical Research Network• N = 1130• Moderately-severe COPD
FEV1/FVC < 70%; FEV1 <80% • “Exacerbation Prone”• Primary Outcome: Time to first AECOPD
The MACRO Study(Azithromycin 250mg/day x 1 year)
NEJM 365:689-98, 2011
Rates of Acute Exacerbations of Chronic Obstructive Pulmonary Disease per Person-Year, According to Study Group.
Albert RK et al. NEJM 2011
Macrolides Decrease AECOPD
10
Ray WA et al. N Engl J Med 2012;366:1881-1890
Ray WA et al. NEJM 2012
Macrolides May Increase risk of Cardiovascular Death
• Macrolides can prolong QT and QTc leading to arrhythmias, including torsades de pointes
• Most arrhythmias with macrolides occur in patients with underlying risk factors
• Incidence of arrhythmias in absence of additional risk factors is very low, perhaps 1 in 100,000.
Mosholder, NEJM 2013
Am J Respir Crit Care Med2014; 189:1173-1180
“Macrolide-associated arrhythmias can be reduced by not prescribing to patients with comorbidities of concern…the majority of which can be discovered by:
• History• ECG before initiating therapy• ECG a short time after initiating therapy”
Am J Respir Crit Care Med2014; 189:1173-1180
Ray WA et al. N Engl J Med 2012;366:1881-1890
Roflumilast
• Oral Tablet• 500 ug Once Daily• Phosphodiesterase-4
Inhibitor
Martinez et al. Lancet 2015
Side Effects, GIDiarrheaWeight Loss
Nausea
11
N Engl J Med. 2014 Jun 5;370(23):2201-10 Wedzicha JA et al. N Engl J Med 2016;374:2222-2234
Wedzicha JA et al. N Engl J Med 2016;374:2222-2234
Rate Ratio
Wedzicha JA et al. N Engl J Med 2016;374:2222-2234
Time ToFirst Exacerbation
Effect of Corticosteroids on Treatment Failure Rates after AE COPD
Niewoehner et al., NEJM 340:1941, 1999
2 week = Solumedrol 125mg q6hr x 3d, Prednisone 60mg qd x 4d, 40mg qd x 4d,20mg qd x 4d
8 week = additional 10mg qd x 5 week, then 5 mg qd x 1 week
Rat
e o
f Tr
eatm
ent
Fai
lure
(%
)
Month
0 1 2 3 4 5 6
60
50
40
20
0
10
308 week
2 week
Placebo
12
Leuppi et alJAMA 2013; 309:2223-2231
• Prednisone, 40 mg/day x 5 daysvs
• Prednisone, 40 mg/day x 14 days
Time to Reexacerbation of COPD
(Intention-to-treat) (Per-Protocol)
Leuppi et al.JAMA 2013;309(21):2223-2231
Summary
• Azithromycin prevents COPD Exacerbations– Potential Risk of Cardiac Arrhythmias
• Roflumilast offers some benefit in bronchitis patients
• 5 days of corticosteroids is the appropriate time frame
• No indication for statins in preventing AECOPD
• Duel Bronchodilators Over ICS
Goals of TreatmentFor Primary Care Physicians
• Improve Symptoms• Prevent Progressive Loss of Lung Function
• Prevention of Acute Exacerbations
13
Effect of Smoking Cessation on FEV1
JAMA 272:1497,1994.
Sustained Quitters2.9
2.8
2.7
2.6
2.5
2.4
Continuing Smokers
Follow-up in years
1 2 3 4 5Screen 2
.
Po
st B
ron
chd
ilato
r F
EV
1(l
iter
s)
Effects of a Smoking Cessation Intervention on 14.5-year Mortality
Anthonisen et alAnn Intern Med 2005; 142:233-239
P=0.03
Smoking Cessation
Usual Care
Celli et alAm J Respir Crit Care Med 178:332-38, 2008
Therapy Reduces Lung Decline(TORCH)
Placebo
Salmeterol + Fluticasone
Tashkin et alNEJM 359:1543-54, 2008
Tiotropium Reduces Lung Decline
14
Downward Spiral In FunctionAssociated With COPD
Disease
DyspneaInactivity
Deconditioning
Pulmonary Rehabilitation • Benefits all levels of disease severity • Reduces respiratory symptoms • Reduces anxiety and depression • Reduces medical and hospital usage • Improves exercise performance • Improves quality of life• Is typically provided as outpatient• Can be initiated as an inpatient until functional
ability has improved
Update on the Management of Asthma
15
Definition of Asthma• Obstruction that is reversible either spontaneously or with treatment; [NAEPP-EPR, 1991]
• Chronic inflammatory disorder (MCs, Eos, Tcells, Macs, PMNs, Epi); variable obstruction; [NAEPP-EPR2, 1997]
• Variable symptoms, obstruction, BHR; inflammation; interaction [NAEPP-EPR3, 2007]
Definition of Asthma• Chronic inflammatory disorder; many different cells; BHR; variable/reversible symptoms and obstruction; phenotypes? [GINA, 2011]
• Heterogeneous; Chronic airway inflammation; variable/reversible symptoms and obstruction;•Different phenotypes or clusters [GINA, 2014]
EPR-3, NHLBI, 2011 Haldar AJRCCM 2008
Asthma Phenotypes
16
Fahy, NRI, 2015
Not all asthma is the same!!(Heterogeneity)(Phenotypes)
Question #4 - Asthma
A. TrueB. False
Inhaled Corticosteroids are effective (at some dose) in all asthmatics.
True or False?
T ru e
F al s e
88%
12%
17
Patients(%)
FEV1 Percent Change From Baseline
302520151050
<-30 -30 to<-20
-20 to<-10
-10 to<0
0 to<10
10 to<20
20 to<30
40 to<50
5030 to<40
Beclomethasone (n=246)Montelukast (n=375)
Patients (≥15 Years) Not Controlled on PRN Beta-Agonists FEV1: Distribution of Individual Patient Responses
Malmstrom et al.Ann Intern Med. 130:487-495, 1999
Eosinophils
Charcot-Leyden Crystals
A Large Subgroup of Mild-to-Moderate AsthmaIs Persistently Noneosinophilic
• Asthma is a heterogeneous disease
• Prior ACRN data (n=995; 2.7 SI; ≥2% eos):• ~50% of asthmatics – poor response to steroids• Eosinophilic airway inflammation not ubiquitous
McGrath et al (ACRN)Am J Respir Crit Care Med 185:612–619, 2012
Sputum Eosinophil Percentage (No ICS)
TH2 Genes Overexpressed in Asthma
Woodruff et alAm J Respir CCM 180:388, 2009
Th2High
Th2High Th2
High
Th2Low
Th2Low Th2
Low
18
Th2 Status Predicts Corticosteroid Response
Woodruff et alAm J Respir CCM 180:388, 2009
• N=135, prednisone x ≥6 months, eosinophils >300
19
A Large Subgroup of Mild-to-Moderate AsthmaIs Persistently Noneosinophilic
• Asthma is a heterogeneous disease
• Prior ACRN data (n=995; 2.7 SI; ≥2% eos):• ~50% of asthmatics – poor response to steroids• Eosinophilic airway inflammation not ubiquitous
McGrath et al (ACRN)Am J Respir Crit Care Med 185:612–619, 2012
Sputum Eosinophil Percentage (No ICS)
Steroids in Eosinophil Negative Asthma (SIENA)
1. Does the response to ICS differ between subjects who are persistently EOS– and
those who are EOS+?
Co-Primary Research Questions:
2. Does the response to LMA differ between subjects who are persistently EOS– and
those who are EOS+?
20
Interim HxLimited PESpiro w/IPB MRSIPeriostineNOEosinophilsGenetics BloodDiary ReviewReview Elig & ComplianceQuestionnaires
EOS-
EOS+
Run-in
Wk 0 3SI SI
SIENA: Schematic
3-month treatment;1st mo censored
3-month treatment;1st mo censored
3-month treatment;1st mo censored
ConsentH&PSpiro w/Alb MR(Mch)CBC, IgEImmunoCAPSIPeriostineNOEosinophilsPregnancy testQuestionnaires
LMA + Int ICS LMA + Int ICS LMA + Int ICS
PBO + Int ICS PBO + Int ICS PBO + Int ICS
PBO + Int ICS PBO + Int ICS PBO + Int ICS
LMA + Int ICS LMA + Int ICS LMA + Int ICS
Phone Visit 18 30 4224 36
Phone Visit
Phone Visit
Phone Visit
Phone Visit
Interim HxLimited PESpiroDiary ReviewQuestionnaires
Interim HxLimited PESpiroDiary ReviewQuestionnaires
Interim HxLimited PESpiroDiary ReviewQuestionnaires
6
RandomizeInterim HxLimited PESpiro(SI)(Periostin)(eNO)Diary ReviewQuestionnaires
12Phone Visit
Phone Visit
Interim HxLimited PESpiroDiary ReviewQuestionnaires
Interim HxLimited PESpiroDiary ReviewQuestionnaires
Interim HxPESpiroDiary ReviewQuestionnairesPregnancy test
Alb MR = Albuterol Maximum Reversibility SI = Sputum InductionIPB MR = Ipratropium Maximum Reversibility ICS = Inhaled CorticosteroidMch = Methacholine PC20 LMA = Long-acting Muscarinic Antagonist
ICS + Int ICS ICS + Int ICS ICS + Int ICS
ICS + Int ICS ICS + Int ICS ICS + Int ICS
Single-blind Placebo
(SI)
Phone VisitV 1 2 3 4 5 6 7 8 9
(See Appendix A for list of Questionnaires)
N = 384Alternative Treatment?
Tiotropium Step-Up for Uncontrolled Asthma
Peters et al.N Engl J Med 363:18, 2010
Eur Respir J; 43:343-73, 2014
21
Eur Respir J; 43:343-73, 2014
Recommendations:• In adults with severe asthma – use sputum eos in experienced centers
• In severe allergic asthma – therapeutic trial of omalizumab
• Do not use methotrexate for asthma• Do not use azithromycin for asthma
Eur Respir J; 43:343-73, 2014
Recommendations:• Use anti-fungals for ABPA• Do not use anti-fungals without ABPA• Consider bronchial thermoplasty only as part of a study
NAEPP GUIDELINES“If there is a clear and positive response for at least 3 months, a careful step down in therapy should be attempted to identify the lowest dose required to maintain control. (Evidence D)””””
Evidence D = Panel Consensus Judgment
Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007.National Asthma Education and Prevention Program.J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94-138.
GINA GUIDELINES“Controller treatment may be stopped if the patient’s asthma remains controlled on the lowest dose of controller and no recurrence of symptoms occurs for 1 year (Evidence D)””””
Global strategy for asthma management and prevention: GINA executive summary.Eur Respir J. 2008 Jan;31(1):143-78.
Evidence D = Panel Consensus Judgment
22
Is There Really A Difference
Between Asthma And COPD?
Pathophysiology in COPD versus Asthma
Asthma• Inflammation• Bronchial hyperresponsiveness• Varying airway obstruction
COPD• Loss of elastic recoil• Changes in small airways• “Inflammation”• Fixed airway obstruction
Inflammation inCOPD versus Asthma
Calverley, Barnes. AJRCCM 2000; 161:341-344
COPD AsthmaPredominant Cells
Macrophages EosinophilsNeutrophils Activated Mast Cells
CD-8 T-Lymphocytes CD-4 T LymphocytesPredominant Cytokines
Interleukin 8 Interleukin 4Leukotriene B4 Interleukin 5
Tumor Necrosis Factor alpha Interleukin 13
COPD Asthma OverlapIN COPD
Postma DS, Rabe KF .N Engl J Med 2015; 373: 1241-1249
23
Asthma Summary
• Asthma not a single disease but a heterogeneous group of diseases
• Patients respond differently to medications based upon underlying “endotype/phenotype”
• “Th2-High” or Allergic Asthma responds to corticosteroids
• Treatments for “Th2-Low” or Non-Allergic Asthma remain unclear
Top Related